LAMISIL 250 mg, scored tablet 28 tablets
Active ingredients: Terbinafine hydrochloride, Terbinafine
Commercialized according to BDPMDispensing in France: Prescription only
Scored tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LAMISIL 250 mg, comprimé sécable
- Pharmaceutical form
- comprimé sécable
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 28 comprimé(s)
- Marketing authorisation holder
- NOVARTIS PHARMA
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 26 May 2025
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66387487CIP73349571CIP133400933495718Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE TERBINAFINEcomprimé | 281,25 mg · un comprimé | SA |
| TERBINAFINEcomprimé | 250 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.